Multiple System Atrophy: all 208 studies
Page 2 of 3. Open to participants first (73), then studies with results posted, then the rest; newest registration first within each.
- [18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy PatientsCompletedNCT06738862
- A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)Active, not recruitingNCT06706622Phase 3
- Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System AtrophyCompletedNCT06671938Phase 2
- A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System AtrophyActive, not recruitingNCT06568237Phase 2
- Biomarkers in Parkinsonian SyndromesActive, not recruitingNCT06501469
- Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the BrainCompletedNCT06445465Early Phase 1
- Synapse Alterations in MSA PatientsCompletedNCT06221644
- Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register StudyActive, not recruitingNCT06209515
- Focused Ultrasound Thalamotomy for Tremor Relief in Atypical ParkinsonismCompletedNCT06204575
- Automated Imaging Differentiation of ParkinsonismActive, not recruitingNCT05913687
- Speech Accessibility ProjectCompletedNCT05889260
- A Biomarker Study of ATH434 in Participants With MSACompletedNCT05864365Phase 2
- Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their CaregiversCompletedNCT05819957Not applicable
- Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech Analysis - Part 2CompletedNCT05807373Not applicable
- Pre-Gene Therapy Study in Parkinson's Disease and Multiple System AtrophyCompletedNCT05699460
- Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)Active, not recruitingNCT05698017Phase 1
- Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)TerminatedNCT05695378Phase 2
- An Observational Study of Parkinson's Disease and Other Synucleinopathies (EASE-PD)CompletedNCT05638815
- Unstructured Eye Tracking as a Diagnostic and Prognostic Biomarker in Parkinsonian DisordersStatus unknownNCT05638477Not applicable
- UB-312 in Patients With SynucleinopathiesCompletedNCT05634876Phase 1
- Transcranial Alternating Current Stimulation (tACS) in Patients With AtaxiaCompletedNCT05621200Not applicable
- Treatment of Transcranial Alternating Current Stimulation（tACS）on Cerebellar AtaxiaCompletedNCT05557786Not applicable
- Observational Study in Multiple System AtrophyActive, not recruitingNCT05453058
- Proof of Mechanism Study to Evaluate Binding of Alfa-synucleinCompletedNCT05274568Phase 1
- Community Outreach for Palliative Engagement -- Parkinson DiseaseActive, not recruitingNCT05222386Not applicable
- Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System AtrophyActive, not recruitingNCT05167721Phase 2
- Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)CompletedNCT05127057Not applicable
- Study of ATH434 in Participants with Multiple System AtrophyCompletedNCT05109091Phase 2
- Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)No longer availableNCT05086094
- Optimization of Morphomer-based Alpha-synuclein PET TracersCompletedNCT05067192
- Manipulating and Optimising Brain Rhythms for Enhancement of SleepCompletedNCT05011773Not applicable
- Quality of Life of Caregivers and Patients Suffering From Multiple System AtrophyCompletedNCT04965922Not applicable
- Complex Eye Movements in Parkinson's Disease and Related Movement DisordersCompletedNCT04925622
- Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System AtrophyStatus unknownNCT04876326Not applicable
- Application of Machine Learning Method in Validation of Screening Cognitive Test for ParkinsonismsCompletedNCT04858893
- Synuclein-One StudyCompletedNCT04700722
- GDNF Gene Therapy for Multiple System AtrophyActive, not recruitingNCT04680065Phase 1
- DBS and SCS Therapy Improve Motor Function in Multiple System Atrophy With Predominant ParkinsonismStatus unknownNCT04617873Not applicable
- Effect of Verdiperstat on Microglial Activation in Well-characterized MSA PatientsCompletedNCT04616456Early Phase 1
- Mobility in Atypical Parkinsonism: a Trial of PhysiotherapyCompletedNCT04608604Not applicable
- Cerebellar rTMS and Physical Therapy for Cerebellar AtaxiaCompletedNCT04595578Not applicable
- Misfolded Proteins in the Skin of People With Parkinson's Disease and Other ParkinsonismCompletedNCT04518059
- Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)CompletedNCT04495582
- Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation ToolkitCompletedNCT04468919Not applicable
- TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System AtrophyCompletedNCT04450992
- TMS Treatment in Multiple System Atrophy With FatigueStatus unknownNCT04313530Not applicable
- Respiratoy Muscle Strength in Patients With Multiple System AtrophyCompletedNCT04287270Not applicable
- Natural History and Disease Progression Biomarkers of Multiple System AtrophyCompletedNCT04229173Not applicable
- Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)CompletedNCT04184063Phase 2
- Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative AtaxiaCompletedNCT04153110Not applicable
- tDCS for Multiple System Atrophy With Cerebellar FeatureStatus unknownNCT04092556Not applicable
- A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With SynucleinopathiesTerminatedNCT04020198
- Trial of Parkinson's And Zoledronic AcidCompletedNCT03924414Phase 4
- Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System AtrophyTerminatedNCT03901638Phase 3
- Exploit the Neural Source and the Feasibility of Transcranial Direct Current Stimulation for Freezing of Gait in Parkinson's Disease and Multiple System AtrophyStatus unknownNCT03721887Not applicable
- Clinical Laboratory Evaluation of Chronic Autonomic FailureCompletedNCT03648905
- Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System AtrophyCompletedNCT03593512Not applicable
- Differential Diagnosis Between Parkinson's Disease and Multiple System Atrophy Using Digital Speech AnalysisCompletedNCT03577483Not applicable
- Automated Abdominal Binder for Orthostatic HypotensionCompletedNCT03482297Phase 1/2
- Cognitive Impairement In Frontotemporal DementiaCompletedNCT03452956
- Safety and Efficacy of Droxidopa for Fatigue in Patients With ParkinsonismWithdrawnNCT03446807Phase 2
- Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical TrialCompletedNCT03403309Phase 2
- Brain Network Activation in Patients With Movement DisordersStatus unknownNCT03269201
- Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System AtrophyCompletedNCT03265444Phase 1
- More Than a Movement Disorder: Applying Palliative Care to Parkinson's DiseaseCompletedNCT03076671Not applicable
- Gait Analysis in Neurological DiseaseActive, not recruitingNCT02994719
- Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic FailureTerminatedNCT02897063Phase 1
- PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UKStatus unknownNCT02778607
- Biomarkers in Neural DisordersCompletedNCT02761707
- Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in AutonomicActive, not recruitingNCT02726711Phase 1
- Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson DiseaseCompletedNCT02640339
- Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic FailureTerminatedNCT02591173Early Phase 1
- Magnetic Resonance Imaging in the Diagnosis of Parkinsonian SyndromesTerminatedNCT02445469Not applicable
- Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic FailureCompletedNCT02429557Phase 1
- Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian SyndromesCompletedNCT02428816Not applicable
- Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSACompletedNCT02270489Phase 1
- 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismCompletedNCT02214862Early Phase 1
- Cognitive and Behavioral Dysexecutive Syndrome in Multiple System AtrophyCompletedNCT02185677
- Water and Sudafed in Autonomic FailureTerminatedNCT02149901Early Phase 1
- Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.CompletedNCT02132052
- Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSACompletedNCT02071459Phase 2/3
- PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)CompletedNCT02035761
- Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)CompletedNCT01888185
- Magnetic Resonance Spectroscopy in Autonomic FailureTerminatedNCT01607268
- Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System AtrophyCompletedNCT01577992Not applicable
- Oligomeric Alpha-synuclein in Multiple System AtrophyCompletedNCT01485549
- Analysis of the Enteric Nervous System Using Colonic BiopsiesCompletedNCT01353183Not applicable
- Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic HypotensionCompletedNCT01316666
- Contribution of Angiotensin II to Supine Hypertension in Autonomic FailureTerminatedNCT01292694Phase 1
- Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's DiseaseCompletedNCT01155492
- Fluoxetine in Multiple System Atrophy PatientsCompletedNCT01146548Phase 2
- Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) StudyCompletedNCT01136213Not applicable
- The Role of Endothelin in the Supine Hypertension of Autonomic FailureWithdrawnNCT01119417Phase 1
- Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (PET) StudyCompletedNCT01044992Not applicable
- Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System AtrophyCompletedNCT00911365Phase 2
- Botulinum A Toxin in Patients With Parkinson's DiseaseStatus unknownNCT00822913Phase 4
- Fipamezole in Neurogenic Orthostatic HypotensionStatus unknownNCT00758849Phase 2
- Assessment of Ambulatory Polygraphy in the Detection of Sleep Apnea in Multiple System Atrophy (SAMSA)CompletedNCT00743561Not applicable
- Autonomic Failure Patients for RNA Blood SamplingCompletedNCT00742586
- Diagnostic and Prognostic Biomarkers in Parkinson DiseaseStatus unknownNCT00653783